Latest Oncologists Stories
NEW YORK, Feb. 8, 2013 /PRNewswire/ -- IBM (NYSE: IBM), WellPoint, Inc. (NYSE: WLP) and Memorial Sloan-Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence based medicine. (Photo: http://photos.prnewswire.com/prnh/20130208/NY57025 )(Logo:...
SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced that four posters highlighting the performance and clinical utility of its Decipher(TM) test will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). Decipher is a transformative genomic decision tool that provides accurate and actionable information to forecast patients that are at risk for lethal prostate cancer. Abstracts will be made available to...
The Clinical Trials Program at Northern Westchester Hospital is excited to present the "MEAL" study in prostate cancer. Westchester, NY (PRWEB) February 05, 2013 The Clinical Trials Program at Northern Westchester Hospital is excited to present the “MEAL” study in prostate cancer. True to its name, The MEAL [Men’s Eating and Living] study focuses on whether a man’s nutrition and diet contribute towards the progression of prostate cancer. Although a simple internet...
SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, and the Knight Cancer Institute at Oregon Health & Science University (OHSU), a national leader in translational oncology research, have formed a collaboration to develop more clinically predictive in vitro three dimensional cancer models which will ultimately...
BETHESDA, Md., Jan. 29, 2013 /PRNewswire/ -- The National Foundation for Cancer Research (NFCR) announced today that Dr. Alex Matter has been awarded the 8(th) Szent-Gyorgyi Prize for Progress in Cancer Research for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer. This first targeted cancer therapy, imatinib mesylate, or Gleevec, contributed to a major breakthrough in the treatment of Chronic Myelogenous Leukemia (CML),...
BALTIMORE, Jan. 29, 2013 /PRNewswire/ -- Chesapeake Urology Associates has been named among the Best Places to Work by Baltimore Magazine for 2013. The annual listing evaluates employers in the Greater Baltimore area on a variety of employment factors including atmosphere or physical work space, potential for career advancement, benefits, compensation, employee- and family-friendly policies, and leadership. Chesapeake Urology was one of 25 companies selected from a field of nearly...
PAACT Announces Its Second 2013 Event Geared Toward Becoming More Informed About Prostate Cancer Grand Rapids, Michigan (PRWEB) January 28, 2013 Prostate cancer charity Patient Advocates for Advanced Cancer Treatments (PAACT) announced that it will be holding its second event of the year on Tuesday, February 5 at 7 p.m., at the Gilda's Club in Grand Rapids. Speaker Dr. Chris Whelan will discuss must-know information about prostate cancer during his presentation titled "Prostate...
INDIANAPOLIS, Jan. 28, 2013 /PRNewswire/ -- PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, announces the following webcast: What: PACE Cancer Perception Index webcastWhen: Wednesday, January 30, 2013, from 11:00 a.m. to 12:00 p.m. ESTWhere: http://www.videonewswire.com/event.asp?id=91886 How: Live over the Internet; simply register via the address above The public's cancer IQ is rising, but myths persist....
Virginia G. Piper Cancer Center data presented at San Francisco ASCO symposium A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study was led by physicians from Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a...
Virginia G. Piper Cancer Center data presented at San Francisco ASCO symposium SCOTTSDALE, Ariz., Jan. 22, 2013 /PRNewswire-USNewswire/ -- A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. (Photo: http://photos.prnewswire.com/prnh/20120201/DC45876) The MPACT (Metastatic Pancreatic...
